BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 20463005)

  • 1. Formation pathways of gamma-butyrolactone from the furan ring of tegafur during its conversion to 5-fluorouracil.
    Yamamiya I; Yoshisue K; Matsushima E; Nagayama S
    Drug Metab Dispos; 2010 Aug; 38(8):1267-76. PubMed ID: 20463005
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytosolic and microsomal activation of doxifluridine and tegafur to produce 5-fluorouracil in human liver.
    Ozawa S; Hamada M; Murayama N; Nakajima Y; Kaniwa N; Matsumoto Y; Fukuoka M; Sawada J; Ohno Y
    Cancer Chemother Pharmacol; 2002 Dec; 50(6):454-8. PubMed ID: 12451471
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bioactivation of tegafur to 5-fluorouracil is catalyzed by cytochrome P-450 2A6 in human liver microsomes in vitro.
    Ikeda K; Yoshisue K; Matsushima E; Nagayama S; Kobayashi K; Tyson CA; Chiba K; Kawaguchi Y
    Clin Cancer Res; 2000 Nov; 6(11):4409-15. PubMed ID: 11106261
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes.
    Komatsu T; Yamazaki H; Shimada N; Nakajima M; Yokoi T
    Drug Metab Dispos; 2000 Dec; 28(12):1457-63. PubMed ID: 11095583
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Anti-angiogenic activities of UFT and its metabolites, GHB and GBL, in the dorsal air sac (DAS) model in mice].
    Basaki Y; Yonekura K; Chikahisa L; Okabe S; Hashimoto A; Miyadera K; Aoyagi K; Yamada Y
    Gan To Kagaku Ryoho; 2000 Jan; 27(1):93-8. PubMed ID: 10660738
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association analysis of CYP2A6 genotypes and haplotypes with 5-fluorouracil formation from tegafur in human liver microsomes.
    Wang H; Bian T; Liu D; Jin T; Chen Y; Lin A; Chen C
    Pharmacogenomics; 2011 Apr; 12(4):481-92. PubMed ID: 21521021
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of CYP2A6 genetic polymorphism on the metabolic conversion of tegafur to 5-fluorouracil and its enantioselectivity.
    Yamamiya I; Yoshisue K; Ishii Y; Yamada H; Chiba M
    Drug Metab Dispos; 2014 Sep; 42(9):1485-92. PubMed ID: 25002745
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enantioselectivity in the cytochrome P450-dependent conversion of tegafur to 5-fluorouracil in human liver microsomes.
    Yamamiya I; Yoshisue K; Ishii Y; Yamada H; Yoshida K
    Pharmacol Res Perspect; 2013 Oct; 1(1):e00009. PubMed ID: 25505563
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Involvement of microsomal cytochrome P450 and cytosolic thymidine phosphorylase in 5-fluorouracil formation from tegafur in human liver.
    Komatsu T; Yamazaki H; Shimada N; Nagayama S; Kawaguchi Y; Nakajima M; Yokoi T
    Clin Cancer Res; 2001 Mar; 7(3):675-81. PubMed ID: 11297264
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of CYP2A6 in tumor cells augments cellular sensitivity to tegafur.
    Murayama N; Sai K; Nakajima Y; Kaniwa N; Ozawa S; Ohno Y; Sawada J
    Jpn J Cancer Res; 2001 May; 92(5):524-8. PubMed ID: 11376561
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The gamma-hydroxybutyrate model of absence seizures: correlation of regional brain levels of gamma-hydroxybutyric acid and gamma-butyrolactone with spike wave discharges.
    Snead OC
    Neuropharmacology; 1991 Feb; 30(2):161-7. PubMed ID: 2030821
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of gamma-hydroxybutylic acid (GHB) and gamma-butyrolactone (GBL), the anti-angiogenic metabolites of oral fluoropyrimidine UFT, in patients with gastric cancer.
    Emi Y; Sumiyoshi Y; Oki E; Kakeji Y; Fukui Y; Maehara Y
    Fukuoka Igaku Zasshi; 2007 Dec; 98(12):418-24. PubMed ID: 18260367
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gamma butyrolactone (GBL) and gamma valerolactone (GVL): similarities and differences in their effects on the acoustic startle reflex and the conditioned enhancement of startle in the rat.
    Marinetti LJ; Leavell BJ; Jones CM; Hepler BR; Isenschmid DS; Commissaris RL
    Pharmacol Biochem Behav; 2012 Jun; 101(4):602-8. PubMed ID: 22349589
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activation of Ftorafue [R,S-1-(tetrahydro-2-furanyl)-5-fluorouracil] to 5-fluorouracil and gamma-butyrolactone.
    Au JL; Sadée W
    Cancer Res; 1980 Aug; 40(8 Pt 1):2814-9. PubMed ID: 6771006
    [No Abstract]   [Full Text] [Related]  

  • 15. The reactivity of gamma-hydroxybutyric acid (GHB) and gamma-butyrolactone (GBL) in alcoholic solutions.
    Hennessy SA; Moane SM; McDermott SD
    J Forensic Sci; 2004 Nov; 49(6):1220-9. PubMed ID: 15568693
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gamma hydroxybutyrate (GHB), gamma butyrolactone (GBL) and 1,4-butanediol (1,4-BD; BDO): A literature review with a focus on UK fatalities related to non-medical use.
    Corkery JM; Loi B; Claridge H; Goodair C; Corazza O; Elliott S; Schifano F
    Neurosci Biobehav Rev; 2015 Jun; 53():52-78. PubMed ID: 25843781
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CYP2A6 and the plasma level of 5-chloro-2, 4-dihydroxypyridine are determinants of the pharmacokinetic variability of tegafur and 5-fluorouracil, respectively, in Japanese patients with cancer given S-1.
    Fujita K; Yamamoto W; Endo S; Endo H; Nagashima F; Ichikawa W; Tanaka R; Miya T; Araki K; Kodama K; Sunakawa Y; Narabayashi M; Miwa K; Ando Y; Akiyama Y; Kawara K; Kamataki T; Sasaki Y
    Cancer Sci; 2008 May; 99(5):1049-54. PubMed ID: 18380793
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel mutant allele of the CYP2A6 gene (CYP2A6*11 ) found in a cancer patient who showed poor metabolic phenotype towards tegafur.
    Daigo S; Takahashi Y; Fujieda M; Ariyoshi N; Yamazaki H; Koizumi W; Tanabe S; Saigenji K; Nagayama S; Ikeda K; Nishioka Y; Kamataki T
    Pharmacogenetics; 2002 Jun; 12(4):299-306. PubMed ID: 12042667
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gamma hydroxybutyrate (GHB) and gamma butyrolactone (GBL) withdrawal: five case studies.
    McDaniel CH; Miotto KA
    J Psychoactive Drugs; 2001; 33(2):143-9. PubMed ID: 11476261
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chronic intragastric administration of gamma-butyrolactone produces physical dependence in baboons.
    Goodwin AK; Griffiths RR; Brown PR; Froestl W; Jakobs C; Gibson KM; Weerts EM
    Psychopharmacology (Berl); 2006 Nov; 189(1):71-82. PubMed ID: 17047936
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.